BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure
Aurase® Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
- Aurase shows dual action on chronic wound debridement and healing
- SolasCure preparing fund raising for clinical phase 2b/3
- Sequential growth forecasted in the next quarters for BRAINBiocatalysts
ZWINGENBERG, Germany, February 25, 2026 – BRAIN Biotech AG, a leading provider of specialty enzymes and innovative biosolutions for industry, has published its financial figures for the first three months of the fiscal year 2025/26.
BRAIN Biotech Group generated Q1 revenue of € 11.9 million compared to € 13.1 million in the same period of the previous year, a decrease of 9.0 %. The group strongly improved the adjusted EBITDA to € 0.3 million from € -0.7 million in the same period last year, reflecting the strong performance of the BRAINBioIncubator segment. The BRAINBioIncubator segment benefitted from a milestone income of € 1.0 million from the deucrictibant program. The core segment BRAINBiocatalysts had the expected slow start to the year but is forecasted to show sequential growth over the next quarters.
“Aurase Wound Gel has demonstrated to accelerate wound debridement and healing at the same time and has therefore the potential to become a best-in-class first line treatment for chronic wounds with a large addressable market
